Case series/case reports (Indigo)
Massive vaccination against COVID-19 has become a global priority. Simultaneously, concerns regarding the safety of vaccines are growing. In this article the authors describe two patients who developed sensory Guillain-Barre syndrome (GBS) shortly after the first dose of the ChAdOx1 vaccine. They also summarize 12 published cases of GBS after ChAdOx1 vaccination, highlighting their unique clinical and paraclinical features. Furthermore, they also propose a possible association between the risk of GBS and the ChAdOx1 vaccine and recommend surveillance for GBS following vaccination. However, they underlined that population-based studies are needed to determine causality and whether specific subpopulations are susceptible.
Min YG, Ju W, Ha YE, Ban JJ, Lee SA, Sung JJ, Shin JY. Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature. J Neuroimmunol. 2021 Aug 8;359:577691. doi: 10.1016/j.jneuroim.2021.577691.
